Cite

HARVARD Citation

    Marshall, J. et al. (2013). Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer. Future oncology. pp. 271-281. [Online]. 
  
Back to record